The estimated Net Worth of Robert J. Meyer is at least $400 Tisíc dollars as of 8 May 2023. Robert Meyer owns over 8,750 units of Telesis Bio Inc stock worth over $59,755 and over the last 7 years he sold TBIO stock worth over $0. In addition, he makes $339,776 as Independent Director at Telesis Bio Inc.
Robert has made over 5 trades of the Telesis Bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 8,750 units of TBIO stock worth $9,975 on 8 May 2023.
The largest trade he's ever made was buying 11,400 units of Telesis Bio Inc stock on 19 May 2022 worth over $23,484. On average, Robert trades about 1,953 units every 71 days since 2018. As of 8 May 2023 he still owns at least 35,150 units of Telesis Bio Inc stock.
You can see the complete history of Robert Meyer stock trades at the bottom of the page.
Dr. Robert Jeyer M.D. serves as Independent Director of the Company. Dr. Meyer has served as a member of our board of directors since January 2019. Since January 2018, Dr. Meyer has been a principal of the drug and biological products team at Greenleaf Health Inc., a U.S. Food and Drug Administration, or FDA, strategic advising company. He is an associate professor of public health sciences at the University of Virginia, and he also served as the director of the Virginia Center for Translational and Regulatory Sciences from March 2013 to December 2017. Prior to joining the faculty at the University of Virginia, Dr. Meyer joined Merck & Co, Inc. in October 2007 and served as vice president and head, global regulatory strategy, policy and safety at Merck Research Laboratories until January 2013. Prior to Merck, Dr. Meyer worked for the FDA from 1994 to 2007. Dr. Meyer holds a B.A. in natural sciences from Lehigh University, and an M.D. from the University of Connecticut School of Medicine, where he also completed his residency in internal medicine and served as chief resident. He completed a fellowship in pulmonary and critical care medicine at the University of Vermont. Dr. Meyer also serves on the board of directors of Chimerix, Inc. and Correvio Pharma Corp. He has been a medical science trustee for the United States Pharmacopeia Board, a non-profit foundation, since April 2015. Meyer is qualified to serve on our board of directors because of his experience advising companies on regulatory matters related to drug approval and as a board member for other public life sciences companies, and because of his practice of medicine.
As the Independent Director of Telesis Bio Inc, the total compensation of Robert Meyer at Telesis Bio Inc is $339,776. There are 5 executives at Telesis Bio Inc getting paid more, with Ronald Renaud having the highest compensation of $3,386,150.
Robert Meyer is 62, he's been the Independent Director of Telesis Bio Inc since 2019. There are 2 older and 10 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk a Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: